Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Accumulated Expenses (2016 - 2020)

Akebia Therapeutics has reported Other Accumulated Expenses over the past 6 years, most recently at $10.3 million for Q1 2020.

  • Quarterly Other Accumulated Expenses fell 39.38% to $10.3 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Mar 2020, down 39.38% year-over-year, with the annual reading at $725000.0 for FY2019, 81.7% down from the prior year.
  • Other Accumulated Expenses was $10.3 million for Q1 2020 at Akebia Therapeutics, up from $725000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $16.9 million in Q1 2019 and troughed at $29000.0 in Q4 2016.
  • The 5-year median for Other Accumulated Expenses is $2.3 million (2017), against an average of $3.8 million.
  • Year-over-year, Other Accumulated Expenses skyrocketed 8068.97% in 2017 and then crashed 98.24% in 2018.
  • A 5-year view of Other Accumulated Expenses shows it stood at $29000.0 in 2016, then skyrocketed by 8068.97% to $2.4 million in 2017, then soared by 67.24% to $4.0 million in 2018, then tumbled by 81.7% to $725000.0 in 2019, then skyrocketed by 1315.59% to $10.3 million in 2020.
  • Per Business Quant, the three most recent readings for AKBA's Other Accumulated Expenses are $10.3 million (Q1 2020), $725000.0 (Q4 2019), and $79000.0 (Q3 2019).